Potential pharmacokinetic interactions between dapoxetine, a serotonin transporter inhibitor developed for the treatment of premature ejaculation (PE), and the phosphodiesterase-5 inhibitors tadalafil and sildenafil, agents used in the treatment of erectile dysfunction (ED), were investigated in an open-label, randomized, crossover study (n ¼ 24 men) comparing dapoxetine 60 mg, dapoxetine 60 mg þ tadalafil 20 mg, and dapoxetine 60 mg þ sildenafil 100 mg. Plasma concentrations of dapoxetine, tadalafil, and sildenafil were determined by liquid chromatography-tandem mass spectrometry. Tadalafil did not affect the pharmacokinetics of dapoxetine, whereas sildenafil increased the dapoxetine AUC inf by 22%; these effects were deemed not clinically important. Dapoxetine did not appear to affect the pharmacokinetics of tadalafil or sildenafil. Most adverse events were mild in nature. Thus, dapoxetine has no clinically important pharmacokinetic interactions with tadalafil or sildenafil, and the combinations are well tolerated.
Introduction
Premature ejaculation (PE) is a common form of male sexual dysfunction, which has been shown to cause significant distress in men and their partners.
1-3 Although they are not indicated for the treatment of PE, conventional selective serotonin reuptake inhibitor (SSRI) antidepressants are commonly used to treat the condition. [4] [5] [6] A new serotonin transporter inhibitor, dapoxetine, has been developed specifically for the treatment of PE. 7 Results from placebo-controlled, randomized, multicenter phase III trials have demonstrated that men with PE receiving dapoxetine 30 or 60 mg experienced increased intravaginal ejaculatory latency and higher levels of control over ejaculation and satisfaction with sexual intercourse. 7 Dapoxetine was effective when taken ondemand, 1-3 h before intercourse. In contrast, largescale studies (N4100) of efficacy and safety in men with PE have not been conducted with conventional SSRI antidepressants, and studies of these agents for the treatment of PE have rarely been placebo controlled. A significant proportion of men with PE also present with erectile dysfunction (ED). 8, 9 While a few of the studies have evaluated the effectiveness of ED treatments in men with comorbid PE and ED, 10, 11 very few have examined the prevalence of these comorbid conditions. A large survey that included 12 134 men from the United States, Germany, and Italy recently found that 7.2% of men met the criteria for both PE and ED. 12 Overall, 32% of men with PE also reported ED, whereas 44% of men with ED also reported PE.
Given the significant proportion of men with both PE and ED, the use of phosphodiesterase (PDE)-5 inhibitors, including tadalafil (CIALIS s ; Lilly ICOS, LLC, Indianapolis, IN, USA) or sildenafil (VIAGRA s ; Pfizer Inc., New York, NY, USA), may be anticipated in patients taking dapoxetine. 9 As such, these PDE-5 inhibitors are likely to be a common concomitant medication, and the potential for drug-drug interactions with dapoxetine must be evaluated.
Dapoxetine is extensively metabolized to numerous phase I and phase II metabolites by multiple cytochrome P450 (CYP) isoforms, with no single enzyme predominating (unpublished data). As there are multiple, parallel pathways for the metabolism of dapoxetine, significant metabolic-based pharmacokinetic interactions between dapoxetine and inhibitors or inducers of CYP isoforms are unlikely. In vitro studies have indicated that tadalafil does not inhibit or induce CYP isoforms, 13 and is therefore not expected to have clinically important pharmacokinetic interactions with dapoxetine. Sildenafil does not induce CYP isoforms in vitro, but may inhibit some CYP isoforms weakly; 14 however, the peak plasma concentrations (1 mM) associated with the maximum dose of 100 mg are unlikely to affect dapoxetine pharmacokinetics or metabolism.
Although the known metabolic pathways and in vitro inhibition and induction results for dapoxetine, sildenafil, and tadalafil suggested that coadministration would result in few pharmacokinetic effects, this definitive clinical study was conducted for several reasons. First, in vitro data do not always reliably predict in vivo pharmacokinetic interactions, 15 and an appropriately designed clinical study is required to evaluate the potential for an in vivo drug-drug interaction definitively. Second, in vitro data do not provide any information regarding the safety and tolerability of concomitantly administered drugs. Even in the absence of a pharmacokinetic drug-drug interaction, it is possible that safety and tolerability may be altered when two drugs are coadministered. Lastly, because many men suffer from both PE and ED and are likely to be treated concomitantly for both conditions, PDE-5 inhibitors are the most likely concomitant medications to be used with dapoxetine. Thus, the potential for interactions must be evaluated in a clinical study.
Consequently, this study investigated the effects of the PDE-5 inhibitors tadalafil and sildenafil on the pharmacokinetics and tolerability of dapoxetine in healthy male volunteers. Sildenafil and tadalafil were chosen as representative PDE-5 inhibitors, because they are commonly prescribed and differ in their pharmacokinetic properties. Sildenafil has a short half-life of about 4 h, 14 while tadalafil has a longer half-life of 17.5 h.
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Materials and methods
Subjects
Healthy males (ages 18-45 years, N ¼ 24) within 20% of normal weight for height and build and with blood pressure (BP) within the range of 90-140 mmHg systolic and 50-90 mmHg diastolic were eligible to participate. Subjects were excluded if they had any clinically relevant abnormalities as determined by medical history, physical examination, blood chemistry, complete blood count (CBC), urinalysis, and electrocardiogram (ECG), or if they had a positive urine drug screen or alcohol breath test. All subjects were required to use a medically acceptable method of contraception throughout the entire study period and for 3 months after study completion. Alcohol, caffeine, and grapefruit consumption were not permitted within 48 h before each dose, and caffeine was limited to p450 mg/ day; smoking or tobacco use within the previous 3 months was not permitted. Subjects were excluded if they had used any prescription or over-thecounter medications (except for acetaminophen or vitamins) within 7 days before each day of dosing, in order to minimize the effect of extraneous factors in the study.
Study design
This was a single-center, open-label, randomized, three-treatment, three-period, six-sequence, crossover study approved by the Ethics Committee (EC) of the study center (Charterhouse Clinical Research Center, Ravenscourt Park Hospital, London, UK), and conducted in accordance with International Conference on Harmonization Good Clinical Practice guidelines, including the ethical principles that have their origin in the Declaration of Helsinki on biomedical research involving human subjects. Before participation, each subject was required to read, sign, and date an EC-approved consent form explaining the nature, purpose, possible risks and benefits, and duration of the study.
Subjects were randomly assigned to one of the six treatment sequences and received each of the following three treatments ( Figure 1 ): a single dose of dapoxetine 60 mg (dapoxetine HCl; Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ, USA); a single dose of dapoxetine 60 mg with a single dose of tadalafil 20 mg; or a single dose of dapoxetine 60 mg with a single dose of sildenafil 100 mg. Each treatment was followed by a washout period of 6-14 days. The study center purchased commercially available tadalafil and sildenafil. The number of subjects enrolled was consistent with that of other drug-drug interaction studies and in accordance with FDA guidelines for in vivo drug metabolism/drug interaction studies.
Assessments
At the initial screening, the following were performed and/or assessed: a physical exam, a medical history, standard laboratory tests (including blood chemistry, CBC (hematocrit, hemoglobin, red blood cell count, white blood cell count with differential, and platelet count), and urinalysis), vital signs (pulse rate (PR), BP, and respiratory rate), a urine Dapoxetine does not interact with PDE-5 inhibitors MJ Dresser et al drug screen, and an ECG. An alcohol breath test and a urine drug screen were performed before each treatment. Vital signs were measured at 0 (predose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, and 72 h following each of the three treatments; an ECG was performed at 0, 2, and 24 h after each dose; and blood samples for pharmacokinetic analysis were collected (as described below). At study termination, a physical exam was performed, along with standard laboratory tests and an ECG, and vital signs were recorded. Subjects were required to fast for 10 h before and 4 h after receiving study medications.
Adverse events (AEs) were assessed in terms of severity and relationship to study drug, and followed until resolution or until the event was medically stable.
Blood sampling and analysis Blood samples (7 ml) for the determination of plasma concentrations of dapoxetine were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48 , and 72 h following each of the three treatments. Tadalafil and sildenafil exposure were confirmed through analysis of blood samples taken at 0, 1, 2, 6, 10, and 24 h and at 0, 1, 2, 6, and 24 h after dosing with dapoxetine þ tadalafil and dapoxetine þ sildenafil, respectively. Plasma samples were analyzed for dapoxetine and the PDE-5 inhibitors using validated liquid chromatography-tandem mass spectrometry (LC/MS/MS) methods.
Briefly, internal standard (dapoxetine-d 7 , tadalafil-d 3 , or sildenafil-d 8 ) was added to plasma samples, and the analytes and internal standards were extracted from plasma. Plasma extracts were evaporated to dryness and reconstituted in an appropriate solvent before injection onto the LC/MS/MS (for dapoxetine, a SCIEX instrument platform with an electrospray ionization interface was used). The assay was validated using samples from this study, with a minimum quantifiable level of 1.00 ng/ml for dapoxetine, tadalafil, and sildenafil.
For dapoxetine, the calibration curve was linear in the range of 1.00-1000 ng/ml, with an average correlation coefficient of 0.9990. The interassay accuracy (% bias) ranged from À3.36 to À1.15, and the interassay precision (% coefficient of variation) ranged from 3.69 to 17.9.
For tadalafil and sildenafil, the calibration curves were linear in the range of 1.00-500 ng/ml, with an average correlation coefficient of 0.995 and 0.9974, respectively. For tadalafil, the interassay accuracy (% bias) ranged from À12.8 to À1.0, and the interassay precision (% coefficient of variation) ranged from 1.4 to 5.3. For sildenafil, the interassay accuracy (% bias) ranged from À4.6 to 7.0, and the interassay precision (% coefficient of variation) ranged from 8.9 to 11.3.
Pharmacokinetic analyses
Pharmacokinetic parameters (maximum plasma concentration, C max ; time to C max , T max ; area under the plasma concentration-versus-time curve, AUC; and half-life, t 1/2 ) were estimated using standard methods. 16 In addition, dapoxetine pharmacokinetics were further characterized using a twocompartment model with first-order absorption and first-order elimination (WinNonMix software, version 2.0.1, Pharsight Corporation, Mountain View, CA, USA).
Statistical analyses
A mixed-effect analysis of variance model, which included treatment, period, sequence, fixed effects, and subject-within-sequence random effect was used to determine if there was a pharmacokinetic interaction between dapoxetine and tadalafil or sildenafil (a ¼ 0.05). 17 Comparison of pharmacokinetic parameters among the three treatment groups was performed according to FDA guidelines, using the least-squares estimate of the mean parameters for the ratios of dapoxetine þ tadalafil and dapox- Figure 1 Randomization protocol. At enrollment, subjects were randomized to one of the six treatment sequences, in which each subject received all three study treatments. Pharmacokinetic analyses were performed for subjects who completed all treatments.
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The Wilcoxon rank-sum test was used to compare T max between treatments. Data from any subject who vomited at or before two times the median T max of study drug were to be excluded from the analyses.
Results
Subject disposition
Of the 24 subjects enrolled, 22 received all three treatments and completed all study procedures. One subject was withdrawn for nonadherence before the second treatment, and another withdrew consent before the third treatment; all were evaluated for safety and tolerability.
Pharmacokinetic analyses
Pharmacokinetic parameters for dapoxetine across the three treatment groups are summarized in Table 1 , and the corresponding plasma concentration profile is presented in Figure 2 . Dapoxetine pharmacokinetics were similar with administration of dapoxetine alone and coadministration of tadalafil or sildenafil; the three treatments demonstrated comparable plasma concentration profiles for dapoxetine. Dapoxetine absorption was rapid, and was not affected by coadministration of tadalafil or sildenafil. Following the peak (i.e., C max ), dapoxetine elimination was rapid and biphasic with all three treatments, with an initial half-life of 1.5-1.6 h and a terminal half-life of 14.8-17.1 h. Plasma dapoxetine concentrations were less than 5% of C max by 24 h. Dapoxetine AUC inf remained unchanged when tadalafil was administered concomitantly; concomitant administration of sildenafil increased the dapoxetine AUC inf by 22% (Table 1) . The analysis methodology is further detailed in the Materials and methods section. 5 and 3.7 h, respectively) . 19, 20 Previously reported values of T max for tadalafil ranged from 30 min to 6 h, which is comparable to the 4.8 h observed with dapoxetine and tadalafil. 13 The observed T max of sildenafil when administered with dapoxetine (1 h) was also similar to the previously reported value for sildenafil (2 h).
Tadalafil and sildenafil
14 Slight differences with established values may have resulted from the limited number of tadalafil samples in the study, which was not designed to definitively assess the pharmacokinetics of tadalafil or sildenafil.
Statistical analyses
The statistical analyses evaluating the effects of tadalafil and sildenafil on log-transformed pharmacokinetic parameters of dapoxetine are summarized in Table 2 .
Tadalafil did not affect the pharmacokinetics of dapoxetine (Table 2) ; the 90% CIs for the mean ratios of C max and of AUC inf were within the standard noeffect boundary of 80-125% 18, 21 for dapoxetine. The T max value for dapoxetine was also unaffected by coadministration of tadalafil (P40.52 for all, by Wilcoxon rank-sum test) ( Table 1) .
Sildenafil had a small effect on dapoxetine pharmacokinetics (Table 2 ). For dapoxetine, the 90% CI of the ratio of dapoxetine þ sildenafil to dapoxetine alone was within the no-effect boundary Dapoxetine does not interact with PDE-5 inhibitors MJ Dresser et al of 80-125% for ln C max (the natural logarithm of C max ), but was outside that range for ln AUC inf . The T max for dapoxetine was comparable between treatments (P ¼ 0.23).
Safety
AEs were reported by 10 of 23 subjects (43.5%) after treatment with dapoxetine alone, by 10 of 23 subjects (43.5%) after dapoxetine þ tadalafil, and by 11 of 23 subjects (47.8%) after dapoxetine þ sildenafil; AEs reported by X2 subjects are listed in Table 3 . Nausea and diarrhea were the most frequently reported AEs. All AEs were of mild or moderate severity, and most were assessed as possibly or probably related to treatment.
Coadministration of tadalafil or sildenafil with dapoxetine did not result in clinically important changes to PR, BP, ECG, or clinical laboratory values during the study or between the pre-and poststudy assessments. Figure 3 shows mean systolic and diastolic BP over time after administration of dapoxetine with or without tadalafil or sildenafil; mean average, minimum, and maximum values for BP and PR are presented in Table 4 .
Discussion
This study investigated the effects of two PDE-5 inhibitors, tadalafil and sildenafil, on the pharmacokinetics and tolerability of dapoxetine, a medication being developed as a treatment for PE. As some patients with PE also have ED, 8, 9 a subset of patients with PE may also be treated for ED using these PDE-5 inhibitors. Results from this study indicate that neither tadalafil nor sildenafil have clinically important effects on the pharmacokinetics and metabolism of dapoxetine, and that dapoxetine has no apparent effect on the pharmacokinetics of tadalafil or sildenafil. This study tested the maximum marketed doses of tadalafil (20 mg) and sildenafil (100 mg), in their approved on-demand dosing regi- Dapoxetine did not appear to affect the pharmacokinetics of tadalafil or sildenafil. While the limited number of samples precluded a definitive characterization of the pharmacokinetics of the two PDE-5 inhibitors, half-life and T max were estimated with the available data, and were similar to previously reported values. 19, 20 These results are in marked contrast to the reported pharmacokinetic interactions reported for tadalafil with ritonavir, ketoconazole, and rifampin, 13 and for sildenafil with ritonavir and erythromycin.
14 Ketoconazole, a selective and potent inhibitor of CYP3A4, increased the tadalafil AUC by 312%, and ritonavir increased the tadalafil AUC by 124%. Rifampin, a CYP3A4 inducer, reduced the tadalafil AUC by 88%.
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Coadministration of sildenafil with the HIV protease inhibitor ritonavir, which is a highly potent CYP inhibitor, resulted in a 1000% increase in the sildenafil AUC.
14 Erythromycin, a specific CYP3A4 inhibitor, increased the sildenafil AUC by 182%.
14 Furthermore, cimetidine, a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when coadministered with sildenafil.
14 These results suggest not only that dapoxetine does not affect the pharmacokinetics of sildenafil and tadalafil but also that dapoxetine does not significantly inhibit or induce CYP3A4 in vivo, as both sildenafil and tadalafil are predominately metabolized by CYP3A4 and have been shown, as outlined above, to be very sensitive to CYP3A4 inhibitors and inducers. This is an important finding, as CYP3A4 is involved in the metabolism of many drugs, and inhibition or induction of this enzyme can result in clinically important drug interactions. 22, 23 The results of this definitive clinical study, which demonstrated no significant pharmacokinetic interactions of dapoxetine with either sildenafil or tadalafil, are in agreement with what is known about the metabolic pathways for dapoxetine and in vitro CYP inhibition and induction profiles for sildenafil and tadalafil. Dapoxetine is extensively metabolized to numerous phase I and phase II metabolites by multiple enzymes, including CYP3A4 and CYP2D6, and in vitro inhibition and induction studies have shown that dapoxetine is a very weak inhibitor of CYP3A4 (unpublished data). Therefore, significant metabolic-based pharmacokinetic interactions between dapoxetine and inhibitors or inducers of CYP isoforms are unlikely.
Tadalafil and sildenafil are reported to be (at most) weak inhibitors and/or inducers of one or more CYP isoforms. Tadalafil reversibly inhibits several CYP isoforms (I/K i ratios of 0.05, 0.03, 0.03, and 0.14 were obtained for CYP3A4, CYP2C9, CYP2C19, and CYP1A2, respectively). 24 As the I/K i ratios for this inhibition are o1, it is unlikely that an interaction between tadalafil and dapoxetine would occur via reversible inhibition. 25 In addition, tadalafil can result in weak mechanism-based inhibition and induction of CYP3A4. However, clinical studies demonstrated that tadalafil does not have clinically significant pharmacokinetic interactions with established in vivo substrates of CYP3A4 (midazolam or lovastatin), suggesting that any in vivo induction and inhibition offset each other. 24 Together, these results and the known metabolism of dapoxetine suggest that tadalafil would not significantly affect the pharmacokinetics of dapoxetine.
Similar to tadalafil, sildenafil is reported to have either no effect or only weak inhibitory effects on CYP isoforms. Sildenafil weakly inhibited the CYP isoforms 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4 (IC 50 4150 mM).
14 As peak plasma concentrations of sildenafil are approximately 1 mM after a 100-mg dose, it is unlikely that sildenafil will alter the clearance of substrates of these isoenzymes. Assuming that the K i values are similar to the reported IC 50 values, the I/K i ratios associated with the inhibition of these enzymes would be o1, suggesting that sildenafil would not appreciably inhibit CYP isoforms in vivo. 25 Therefore, sildenafil and dapoxetine were unlikely to have clinically significant pharmacokinetic interactions.
Based on the results of this study and what is known about the metabolism of vardenafil and sildenafil, it is reasonable to anticipate that vardenafil would not significantly alter the pharmacokinetics of dapoxetine and that dapoxetine would not alter the pharmacokinetics of vardenafil. As is the case with sildenafil and tadalafil, vardenafil is metabolized predominantly by CYP3A4, and has either no or only weak inhibitory effects on CYP isoforms. 26 However, definitive statements cannot be made, as the combination of vardenafil and dapoxetine was not evaluated in this clinical trial.
The incidence of nausea appears to increase when dapoxetine is administered with tadalafil or sildenafil, whereas the incidence of diarrhea appears to decrease. It is difficult to draw definitive conclusions regarding these findings, as phase I drug-drug interaction studies are not sufficiently powered to evaluate differences between AE profiles.
The lack of pharmacokinetic interaction between dapoxetine and tadalafil or sildenafil has important implications for the treatment of men presenting with both PE and ED. Conventional SSRI antidepressants may be used in the treatment of PE, but have been associated with increased side effects in combination with PDE-5 inhibitors; combination therapy using paroxetine (10 mg daily for 21 days, followed by 20 mg as needed) and sildenafil (50 mg as needed) resulted in a significant increase in the incidence of side effects compared to paroxetine alone. 27 To have an effect on PE, conventional SSRIs usually require chronic daily dosing; 28 however, Dapoxetine does not interact with PDE-5 inhibitors MJ Dresser et al this schedule may increase the probability of metabolic interactions with PDE-5 inhibitors and may cause unwanted sexual side effects. By contrast, dapoxetine is effective on the first dose, may be taken on-demand, has minimal accumulation, has a low incidence of unwanted sexual side effects, 7 and does not have clinically relevant pharmacokinetic interactions with the PDE-5 inhibitors tadalafil and sildenafil.
Conclusions
Definitive clinical assessment has demonstrated that tadalafil 20 mg and sildenafil 100 mg have no clinically important effects on the pharmacokinetics of dapoxetine 60 mg. Similarly, dapoxetine did not appear to alter the pharmacokinetics of tadalafil or sildenafil, and the combinations were well tolerated.
